Theriva Biologics, Inc. Research and Development Expense
Theriva Biologics, Inc. (TOVX) reported Research and Development Expense of $1.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Theriva Biologics, Inc. research and development expense for the quarter ending 2026-06-30 was $1.27M, a 35.07% decline year-over-year.
- Theriva Biologics, Inc. research and development expense for the quarter ending 2026-03-31 was $355.00K, a 88.04% decline year-over-year.
- Theriva Biologics, Inc. research and development expense for the quarter ending 2025-12-31 was $1.13M, a 60.78% decline year-over-year.
- Theriva Biologics, Inc. research and development expense for the quarter ending 2025-09-30 was $2.55M, a 6.69% decline year-over-year.
- Theriva Biologics, Inc. research and development expense for fiscal 2025 was $8.60M, a 28.48% decline from fiscal 2024.
- Theriva Biologics, Inc. research and development expense for fiscal 2024 was $12.03M, a 15.93% decline from fiscal 2023.
- Theriva Biologics, Inc. research and development expense for fiscal 2023 was $14.31M, a 22.08% increase from fiscal 2022.
- Theriva Biologics, Inc. research and development expense for fiscal 2022 was $11.72M, a 50.29% increase from fiscal 2021.
| Period end | Research and Development Expense 0 month | Research and Development Expense 0 month as first filed | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.27M 10-Q · filed 2026-08-11 | $1.62M 10-Q · filed 2026-08-11 | $2.75M derived: sum of 3 quarters · filed 2026-08-11 | $5.31M derived: sum of 4 quarters · filed 2026-08-11 | ||||||
| 2026-03-31 | $355.00K 10-Q · filed 2026-05-05 | $1.49M derived: sum of 2 quarters · filed 2026-05-05 | $4.04M derived: sum of 3 quarters · filed 2026-05-05 | $5.99M derived: sum of 4 quarters · filed 2026-08-11 | ||||||
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.68M derived: sum of 2 quarters · filed 2026-03-12 | $5.64M derived: sum of 3 quarters · filed 2026-08-11 | $8.60M 10-K · filed 2026-03-12 | ||||||
| 2025-09-30 | $2.55M 10-Q · filed 2025-11-12 | $4.50M derived: sum of 2 quarters · filed 2026-08-11 | $7.47M 10-Q · filed 2025-11-12 | $10.36M derived: sum of 4 quarters · filed 2026-08-11 | ||||||
| 2025-06-30 | $1.95M 10-Q · filed 2026-08-11 | $4.92M 10-Q · filed 2026-08-11 | $7.81M derived: sum of 3 quarters · filed 2026-08-11 | $10.54M derived: sum of 4 quarters · filed 2026-08-11 | ||||||
| 2025-03-31 | $2.97M 10-Q · filed 2026-05-05 | $5.85M derived: sum of 2 quarters · filed 2026-05-05 | $8.59M derived: sum of 3 quarters · filed 2026-05-05 | $11.54M derived: sum of 4 quarters · filed 2026-05-05 | ||||||
| 2024-12-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.62M derived: sum of 2 quarters · filed 2026-03-12 | $8.57M derived: sum of 3 quarters · filed 2026-03-12 | $12.03M 10-K · filed 2026-03-12 | ||||||
| 2024-09-30 | $2.73M 10-Q · filed 2025-11-12 | $5.69M derived: sum of 2 quarters · filed 2025-11-12 | $9.14M 10-Q · filed 2025-11-12 | $13.34M derived: sum of 4 quarters · filed 2025-11-12 | ||||||
| 2024-06-30 | $2.95M 10-Q · filed 2025-08-11 | $6.41M 10-Q · filed 2025-08-11 | $10.61M derived: sum of 3 quarters · filed 2025-08-11 | $14.61M derived: sum of 4 quarters · filed 2025-08-11 | ||||||
| 2024-03-31 | $3.46M 10-Q · filed 2025-05-14 | $7.66M derived: sum of 2 quarters · filed 2025-05-14 | $11.66M derived: sum of 3 quarters · filed 2025-05-14 | $14.79M derived: sum of 4 quarters · filed 2025-05-14 | ||||||
| 2023-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $8.20M derived: sum of 2 quarters · filed 2025-03-06 | $11.34M derived: sum of 3 quarters · filed 2025-03-06 | $14.31M 10-K · filed 2025-03-06 | ||||||
| 2023-09-30 | $4.01M 10-Q · filed 2024-11-12 | $7.14M derived: sum of 2 quarters · filed 2024-11-12 | $10.12M 10-Q · filed 2024-11-12 | $13.19M derived: sum of 4 quarters · filed 2024-11-12 | ||||||
| 2023-06-30 | $3.13M 10-Q · filed 2024-08-13 | $6.11M 10-Q · filed 2024-08-13 | $9.18M derived: sum of 3 quarters · filed 2024-08-13 | $11.75M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $2.98M 10-Q · filed 2024-05-07 | $6.05M derived: sum of 2 quarters · filed 2024-05-07 | $8.62M derived: sum of 3 quarters · filed 2024-05-07 | $12.10M derived: sum of 4 quarters · filed 2024-05-07 | ||||||
| 2022-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $5.64M derived: sum of 2 quarters · filed 2024-03-25 | $9.13M derived: sum of 3 quarters · filed 2024-03-25 | $11.72M 10-K · filed 2024-03-25 | ||||||
| 2022-09-30 | $2.57M 10-Q · filed 2023-11-13 | $6.05M derived: sum of 2 quarters · filed 2023-11-13 | $8.65M 10-Q · filed 2023-11-13 | $11.43M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | $3.48M 10-Q · filed 2023-08-08 | $6.08M 10-Q · filed 2023-08-08 | $8.86M derived: sum of 3 quarters · filed 2023-08-08 | $10.83M derived: sum of 4 quarters · filed 2023-08-08 | ||||||
| 2022-03-31 | $2.60M 10-Q · filed 2023-05-11 | $5.38M derived: sum of 2 quarters · filed 2023-05-11 | $7.35M derived: sum of 3 quarters · filed 2023-05-11 | $9.28M derived: sum of 4 quarters · filed 2023-05-11 | ||||||
| 2021-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.75M derived: sum of 2 quarters · filed 2023-03-30 | $6.68M derived: sum of 3 quarters · filed 2023-03-30 | $7.80M 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | $1.97M 10-Q · filed 2022-11-10 | $3.90M derived: sum of 2 quarters · filed 2022-11-10 | $5.02M 10-Q · filed 2022-11-10 | $6.00M derived: sum of 4 quarters · filed 2022-11-10 | ||||||
| 2021-06-30 | $1.93M 10-Q · filed 2022-08-11 | $3.05M 10-Q · filed 2022-08-11 | $4.03M derived: sum of 3 quarters · filed 2022-08-11 | $4.94M derived: sum of 4 quarters · filed 2022-08-11 | ||||||
| 2021-03-31 | $1.12M 10-Q · filed 2022-05-16 | $2.10M derived: sum of 2 quarters · filed 2022-05-16 | $3.01M derived: sum of 3 quarters · filed 2022-05-16 | $4.61M derived: sum of 4 quarters · filed 2022-05-16 | ||||||
| 2020-12-31 | $979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $1.89M derived: sum of 2 quarters · filed 2022-03-16 | $3.50M derived: sum of 3 quarters · filed 2022-03-16 | $5.13M 10-K · filed 2022-03-16 | ||||||
| 2020-09-30 | $914.00K 10-Q · filed 2021-11-03 | $2.52M derived: sum of 2 quarters · filed 2021-11-03 | $4.15M 10-Q · filed 2021-11-03 | $6.08M derived: sum of 4 quarters · filed 2021-11-03 | ||||||
| 2020-06-30 | $1.60M 10-Q · filed 2021-08-05 | $3.24M 10-Q · filed 2021-08-05 | $5.17M derived: sum of 3 quarters · filed 2021-08-05 | $9.31M derived: sum of 4 quarters · filed 2021-08-05 | ||||||
| 2020-03-31 | $1.64M 10-Q · filed 2021-05-05 | $3.56M derived: sum of 2 quarters · filed 2021-05-05 | $7.71M derived: sum of 3 quarters · filed 2021-05-05 | $10.30M derived: sum of 4 quarters · filed 2021-05-05 | ||||||
| 2019-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $6.07M derived: sum of 2 quarters · filed 2021-03-04 | $8.66M derived: sum of 3 quarters · filed 2021-03-04 | $11.08M 10-K · filed 2021-03-04 | ||||||
| 2019-09-30 | $4.14M 10-Q · filed 2020-11-10 | $6.74M derived: sum of 2 quarters · filed 2020-11-10 | $9.16M 10-Q · filed 2020-11-10 | $11.21M derived: sum of 4 quarters · filed 2020-11-10 | ||||||
| 2019-06-30 | $2.59M 10-Q · filed 2020-08-06 | $5.01M 10-Q · filed 2020-08-06 | $7.07M derived: sum of 3 quarters · filed 2020-08-06 | $9.91M derived: sum of 4 quarters · filed 2020-08-06 | ||||||
| 2019-03-31 | $2.42M 10-Q · filed 2020-05-05 | $4.47M derived: sum of 2 quarters · filed 2020-05-05 | $7.32M derived: sum of 3 quarters · filed 2020-05-05 | $10.89M derived: sum of 4 quarters · filed 2020-05-05 | ||||||
| 2018-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $4.90M derived: sum of 2 quarters · filed 2020-02-20 | $8.47M derived: sum of 3 quarters · filed 2020-02-20 | $11.84M 10-K · filed 2020-02-20 | ||||||
| 2018-09-30 | $2.85M 10-Q · filed 2019-11-04 | $6.42M derived: sum of 2 quarters · filed 2019-11-04 | $9.79M 10-Q · filed 2019-11-04 | $13.54M derived: sum of 4 quarters · filed 2019-11-04 | ||||||
| 2018-09-05 | $198.00K 10-K · filed 2021-03-04 | $102.00K 10-K · filed 2019-02-27 | ||||||||
| 2018-06-30 | $3.57M 10-Q · filed 2019-08-08 | $6.94M 10-Q · filed 2019-08-08 | $10.70M derived: sum of 3 quarters · filed 2019-08-08 | $14.84M derived: sum of 4 quarters · filed 2019-08-08 | ||||||
| 2018-03-31 | $3.37M 10-Q · filed 2019-05-08 | $7.13M derived: sum of 2 quarters · filed 2019-05-08 | $11.26M derived: sum of 3 quarters · filed 2019-05-08 | $16.09M derived: sum of 4 quarters · filed 2019-05-08 | ||||||
| 2017-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $7.89M derived: sum of 2 quarters · filed 2019-02-27 | $12.72M derived: sum of 3 quarters · filed 2019-02-27 | $18.78M 10-K · filed 2019-02-27 | ||||||
| 2017-09-30 | $4.14M 10-Q · filed 2018-11-08 | $8.97M derived: sum of 2 quarters · filed 2018-11-08 | $15.03M 10-Q · filed 2018-11-08 | $21.76M derived: sum of 4 quarters · filed 2018-11-08 | ||||||
| 2017-06-30 | $4.83M 10-Q · filed 2018-08-08 | $10.89M 10-Q · filed 2018-08-08 | $17.62M derived: sum of 3 quarters · filed 2018-08-08 | $24.68M derived: sum of 4 quarters · filed 2018-08-08 | ||||||
| 2017-03-31 | $6.06M 10-Q · filed 2018-05-08 | $12.79M derived: sum of 2 quarters · filed 2018-05-08 | $19.85M derived: sum of 3 quarters · filed 2018-05-08 | $27.01M derived: sum of 4 quarters · filed 2018-05-08 | ||||||
| 2016-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $13.79M derived: sum of 2 quarters · filed 2018-02-22 | $20.95M derived: sum of 3 quarters · filed 2018-02-22 | $29.11M 10-K · filed 2018-02-22 | ||||||
| 2016-09-30 | $7.06M 10-Q · filed 2017-11-01 | $14.22M derived: sum of 2 quarters · filed 2017-11-01 | $22.38M 10-Q · filed 2017-11-01 | $31.24M derived: sum of 4 quarters · filed 2018-02-22 | ||||||
| 2016-06-30 | $7.16M 10-Q · filed 2017-08-03 | $15.32M 10-Q · filed 2017-08-03 | $24.18M derived: sum of 3 quarters · filed 2018-02-22 | $34.22M derived: sum of 4 quarters · filed 2018-02-22 | ||||||
| 2016-03-31 | $8.15M 10-Q · filed 2017-05-04 | $17.01M derived: sum of 2 quarters · filed 2018-02-22 | $27.06M derived: sum of 3 quarters · filed 2018-02-22 | $34.57M derived: sum of 4 quarters · filed 2018-02-22 | ||||||
| 2015-12-31 | $8.86M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $18.90M derived: sum of 2 quarters · filed 2018-02-22 | $26.41M derived: sum of 3 quarters · filed 2018-02-22 | $32.91M 10-K · filed 2018-02-22 | ||||||
| 2015-09-30 | $10.05M 10-Q · filed 2016-11-01 | $17.55M derived: sum of 2 quarters · filed 2016-11-01 | $24.05M 10-Q · filed 2016-11-01 | $29.29M derived: sum of 4 quarters · filed 2017-03-02 | ||||||
| 2015-06-30 | $7.51M 10-Q · filed 2016-08-03 | $14.00M 10-Q · filed 2016-08-03 | $19.24M derived: sum of 3 quarters · filed 2017-03-02 | $22.94M derived: sum of 4 quarters · filed 2017-03-02 | ||||||
| 2015-03-31 | $6.49M 10-Q · filed 2016-05-05 | $11.74M derived: sum of 2 quarters · filed 2017-03-02 | $15.43M derived: sum of 3 quarters · filed 2017-03-02 | $18.27M derived: sum of 4 quarters · filed 2017-03-02 | ||||||
| 2014-12-31 | $5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $8.94M derived: sum of 2 quarters · filed 2017-03-02 | $11.77M derived: sum of 3 quarters · filed 2017-03-02 | $14.49M 10-K · filed 2017-03-02 | ||||||
| 2014-09-30 | $3.69M 10-Q · filed 2015-11-05 | $6.53M derived: sum of 2 quarters · filed 2015-11-05 | $9.25M 10-Q · filed 2015-11-05 | $11.96M derived: sum of 4 quarters · filed 2016-03-10 | ||||||
| 2014-06-30 | $2.84M 10-Q · filed 2015-08-10 | $5.55M 10-Q · filed 2015-08-10 | $8.27M derived: sum of 3 quarters · filed 2016-03-10 | $9.74M derived: sum of 4 quarters · filed 2016-03-10 | ||||||
| 2014-03-31 | $2.72M 10-Q · filed 2015-05-11 | $5.43M derived: sum of 2 quarters · filed 2016-03-10 | $6.90M derived: sum of 3 quarters · filed 2016-03-10 | $8.11M derived: sum of 4 quarters · filed 2016-03-10 | ||||||
| 2013-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $4.19M derived: sum of 2 quarters · filed 2016-03-10 | $5.39M derived: sum of 3 quarters · filed 2016-03-10 | $6.51M 10-K · filed 2016-03-10 | ||||||
| 2013-09-30 | $1.48M 10-Q · filed 2014-11-14 | $2.68M derived: sum of 2 quarters · filed 2014-11-14 | $3.80M 10-Q · filed 2014-11-14 | $14.39M derived: sum of 4 quarters · filed 2015-03-16 | ||||||
| 2013-06-30 | $1.20M 10-Q · filed 2014-08-14 | $2.32M 10-Q · filed 2014-08-14 | $12.91M derived: sum of 3 quarters · filed 2015-03-16 | $13.68M derived: sum of 4 quarters · filed 2015-03-16 | ||||||
| 2013-03-31 | $1.12M 10-Q · filed 2014-05-15 | $11.71M derived: sum of 2 quarters · filed 2015-03-16 | $12.47M derived: sum of 3 quarters · filed 2015-03-16 | $13.02M derived: sum of 4 quarters · filed 2015-03-16 | ||||||
| 2012-12-31 | $10.59M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $11.35M derived: sum of 2 quarters · filed 2015-03-16 | $11.90M derived: sum of 3 quarters · filed 2015-03-16 | $12.29M 10-K · filed 2015-03-16 | ||||||
| 2012-10-31 | $7.60M 10-Q · filed 2012-11-14 | |||||||||
| 2012-09-30 | $763.00K 10-Q · filed 2013-11-14 | $1.31M derived: sum of 2 quarters · filed 2013-11-14 | $1.70M 10-Q · filed 2013-11-14 | $4.24M derived: sum of 4 quarters · filed 2013-11-14 | ||||||
| 2012-06-30 | $547.00K 10-Q · filed 2013-08-14 | $933.00K 10-Q · filed 2013-08-14 | $3.47M derived: sum of 3 quarters · filed 2013-08-14 | $3.76M derived: sum of 4 quarters · filed 2013-08-14 | ||||||
| 2012-03-31 | $386.00K 10-Q · filed 2013-05-15 | $2.92M derived: sum of 2 quarters · filed 2013-05-15 | $3.21M derived: sum of 3 quarters · filed 2013-05-15 | $3.50M derived: sum of 4 quarters · filed 2013-05-15 | ||||||
| 2011-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-16 | $2.83M derived: sum of 2 quarters · filed 2013-04-16 | $3.11M derived: sum of 3 quarters · filed 2013-04-16 | $3.34M 10-K · filed 2013-04-16 | ||||||
| 2011-09-30 | $289.00K 10-Q · filed 2012-11-14 | $288.96K 10-Q · filed 2011-11-14 | $570.00K derived: sum of 2 quarters · filed 2012-11-14 | $801.00K 10-Q · filed 2012-11-14 | $800.92K 10-Q · filed 2011-11-14 | $1.42M derived: sum of 4 quarters · filed 2012-11-14 | ||||
| 2011-06-30 | $281.00K 10-Q/A · filed 2012-09-11 | $279.64K 10-Q · filed 2011-08-15 | $512.00K 10-Q/A · filed 2012-09-11 | $511.96K 10-Q · filed 2011-08-15 | $1.13M derived: sum of 3 quarters · filed 2012-09-11 | $1.36M derived: sum of 4 quarters · filed 2012-09-11 | ||||
| 2011-03-31 | $231.00K 10-Q · filed 2012-05-15 | $848.23K derived: sum of 2 quarters · filed 2012-05-15 | $1.08M derived: sum of 3 quarters · filed 2012-05-15 | $1.50M derived: sum of 4 quarters · filed 2012-05-15 | ||||||
| 2010-12-31 | $617.23K derived: 10-K/A 12 month − 10-Q 9 month · filed 2012-05-11 | $846.28K derived: sum of 2 quarters · filed 2012-05-11 | $1.27M derived: sum of 3 quarters · filed 2012-05-11 | $1.58M 10-K/A · filed 2012-05-11 | ||||||
| 2010-09-30 | $229.04K 10-Q · filed 2011-11-14 | $655.62K derived: sum of 2 quarters · filed 2011-11-14 | $962.77K 10-Q · filed 2011-11-14 | |||||||
| 2010-06-30 | $426.57K 10-Q · filed 2011-08-15 | $733.72K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |